Your browser doesn't support javascript.
Seroprevalence of SARS-CoV-2 antibodies in Seattle, Washington: October 2019-April 2020.
McCulloch, Denise J; Jackson, Michael L; Hughes, James P; Lester, Sandra; Mills, Lisa; Freeman, Brandi; Rasheed, Mohammad Ata Ur; Thornburg, Natalie J; Chu, Helen Y.
  • McCulloch DJ; School of Medicine, University of Washington, Seattle, Washington, United States of America.
  • Jackson ML; Kaiser Permanente Washington, Seattle, Washington, United States of America.
  • Hughes JP; Department of Biostatistics, School of Public Health, University of Washington, Seattle, Washington, United States of America.
  • Lester S; Synergy America, Inc., Duluth, Georgia, United States of America.
  • Mills L; Eagle Global Scientific, LLC, Atlanta, Georgia, United States of America.
  • Freeman B; Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Rasheed MAU; Synergy America, Inc., Duluth, Georgia, United States of America.
  • Thornburg NJ; Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Chu HY; School of Medicine, University of Washington, Seattle, Washington, United States of America.
PLoS One ; 16(5): e0252235, 2021.
Article in English | MEDLINE | ID: covidwho-1247654
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT

BACKGROUND:

The first US case of SARS-CoV-2 infection was detected on January 20, 2020. However, some serology studies suggest SARS-CoV-2 may have been present in the United States prior to that, as early as December 2019. The extent of domestic COVID-19 detection prior to 2020 has not been well-characterized.

OBJECTIVES:

To estimate the prevalence of SARS-CoV-2 antibody among healthcare users in the greater Seattle, Washington area from October 2019 through early April 2020. STUDY

DESIGN:

We tested residual samples from 766 Seattle-area adults for SARS-CoV-2 antibodies utilizing an ELISA against prefusion-stabilized Spike (S) protein.

RESULTS:

No antibody-positive samples were found between October 2, 2019 and March 13, 2020. Prevalence rose to 1.2% in late March and early April 2020.

CONCLUSIONS:

The absence of SARS-CoV-2 antibody-positive samples in October 2019 through mid-March, 2020, provides evidence against widespread circulation of COVID-19 among healthcare users in the Seattle area during that time. A small proportion of this metropolitan-area cohort had been infected with SARS-CoV-2 by spring of 2020.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Serological Testing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study Limits: Adult / Female / Humans / Male Country/Region as subject: North America Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Journal.pone.0252235

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Serological Testing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study Limits: Adult / Female / Humans / Male Country/Region as subject: North America Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Journal.pone.0252235